AZN - 3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors
Big cash flows from a handful of successful new cancer drugs recently emboldened AstraZeneca (NASDAQ: AZN) to make a huge bet on Alexion Pharmaceuticals (NASDAQ: ALXN) and its successful drugs for rare diseases. AstraZeneca offered $39 billion for Alexion in a combination of cash and stock, although a lack of enthusiasm for the deal has pressed AstraZeneca shares lower since the announcement.
Granted, Alexion Pharmaceuticals isn't the industry's most exciting acquisition target, but this deal will most likely work out well for investors in the long run. Here are three big reasons this deal looks like a win-win for both drugmakers and their shareholders.
Image source: Getty Images.
For further details see:
3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors